Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 377 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain April 1, 2022 Stopping the spread: A revolution in how we think about metastasis October 18, 2022 Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... November 28, 2023 Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... July 18, 2023 Load more HOT NEWS Biopsie: 5 lucruri pe care fiecare pacient trebuie să le cunoască What is Mindfulness? ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... Man Walks Entire Continent To Spread Awareness About Mental Health &...
